Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · Real-Time Price · USD
8.33
+0.27 (3.35%)
At close: Jul 14, 2025, 4:00 PM
8.35
+0.02 (0.22%)
After-hours: Jul 14, 2025, 4:33 PM EDT
Company Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Robert Barrow |
Contact Details
Address: One World Trade Center, Suite 8500 New York, New York 10007 United States | |
| Phone | 212 220 6633 |
| Website | mindmed.co |
Stock Details
| Ticker Symbol | MNMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001813814 |
| CUSIP Number | 60255C109 |
| ISIN Number | CA60255C8850 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Robert Barrow | Chief Executive Officer and Director |
| Mark R. Sullivan J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
| Dr. Scott M. Freeman M.D. | Co-Founder and Clinical Advisor |
| Leonard Latchman | Co-Founder |
| Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer |
| Peter Mack | Senior Vice President of Pharmaceutical Development and Operations |
| Carrie F. Liao CPA, CGMA | Vice President and Chief Accounting Officer |
| Beth Calitri | Vice President of Corporate Communications |
| Stephanie Fagan | Chief Corporate Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | 144 | Filing |
| Jun 25, 2025 | 144 | Filing |
| Jun 25, 2025 | 144 | Filing |
| Jun 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 16, 2025 | 8-K | Current Report |
| May 27, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| May 5, 2025 | D | Notice of Exempt Offering of Securities |